IP Library Granted Patent US 8,288,372
Granted Patent B2
US 8,288,372 · App. 10/719,540 · Granted Oct 16, 2012

Method for treating headache with loxapine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,288,372
App. No.
10/719,540
Granted
Oct 16, 2012
Kind
B2
Abstract

Loxapine, amoxapine, or salts or prodrugs of either, is effective in alleviating pain, particularly headache pain such as migraine, cluster headaches and tension headaches. Preferably the loxapine or amoxapine is administered systemically, most preferably by inhalation.

Claims (16)

1. A method for treating headache comprising administering to a subject in need of headache relief, an effective amount of a compound selected from the group consisting of loxapine, pharmaceutically acceptable salts of loxapine, and prodrugs of loxapine wherein 0.3 to 6.0 mg of loxapine is administered, or an amount of a salt or prodrug of loxapine is administered that produces in the subject a blood concentration of loxapine equivalent to the administration of 0.3 to about 6.0 mg of loxapine.

2. A method in accordance with claim 1 , wherein said headache is a migraine headache.

3. A method in accordance with claim 1 , wherein said headache is a cluster headache.

4. A method in accordance with claim 1 , wherein said headache is a tension-type headache.

5. A method in accordance with claim 1 , wherein said compound is administered by inhalation.

6. A method in accordance with claim 1 , wherein said subject is human, said headache is a migraine headache, and said compound is administered by inhalation.

7. A method in accordance with claim 1 , wherein the compound is formulated so as to result in a maximum blood level of loxapine within about 30 minutes from administration.

8. A method in accordance with claim 1 , wherein the compound is formulated so as to result in a maximum blood level of loxapine within about 15 minutes from administration.

9. A method in accordance with claim 1 , wherein the compound is formulated so as to result in a peak rate of increase in the blood level of loxapine of at least about 1 ng/ml/minute.

10. A method in accordance with claim 1 , wherein the compound is formulated so as to result in a blood level of loxapine of at least about 5 ng/ml within about 15 minutes from administration.

11. A method in accordance with claim 1 , wherein said compound is administered via inhalation using a rapid-heating drug delivery article or a thin-film drug delivery article.

12. A method in accordance with claim 1 , wherein said compound is administered via an inhalation delivery device, wherein said compound is vaporized and condensed to provide at least 50% recovery of said compound in an aerosol, and wherein said aerosol contains less than about 5% by weight of compound degradation products.

13. A method in accordance with claim 12 , wherein said compound is coated on a substrate in the delivery device as a film having a thickness between about 0.5 and 20 μm.

14. A method in accordance with claim 1 , wherein said compound is administered in the form of an aerosol having a mass median aerodynamic diameter of between about 0.01 and about 3 μm.

15. A method in accordance with claim 1 , wherein said compound is administered via a rapid heating drug delivery article, and wherein said compound is volatized from a compound composition film under conditions sufficient to provide an aerosol having at least 50% recovery of said compound and containing less than about 10% by weight of compound degradation products.

16. A method for treating headache pain in a subject comprising administering to said subject an effective amount of a compound selected from the group consisting of loxapine, pharmaceutically acceptable salts of loxapine and prodrugs of loxapine wherein 0.3 to 6.0 mg of loxapine is administered, or an amount of a salt or prodrug of loxapine is administered that produces in the subject a blood concentration of loxapine equivalent to the administration of 0.3 to about 6.0 mg of loxapine.

Assignments (2)
CHANGE OF NAME Recorded Oct 18, 2005
From: ALEXZA MOLECULAR DELIVERY CORPORATION
To: ALEXZA PHARMACEUTICALS, INC.
Reel/Frame 016926/0674 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2003
From: HALE, RON L.; MUNZAR, PATRIK; RABINOWITZ, JOSHUA D.
To: ALEXZA MOLECULAR DELIVERY CORPORATION
Reel/Frame 014747/0304 →